AR056712A1 - Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus - Google Patents

Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus

Info

Publication number
AR056712A1
AR056712A1 ARP060104591A ARP060104591A AR056712A1 AR 056712 A1 AR056712 A1 AR 056712A1 AR P060104591 A ARP060104591 A AR P060104591A AR P060104591 A ARP060104591 A AR P060104591A AR 056712 A1 AR056712 A1 AR 056712A1
Authority
AR
Argentina
Prior art keywords
influenza virus
virus
influenza
inoculation
immunogen
Prior art date
Application number
ARP060104591A
Other languages
English (en)
Inventor
Kim Gugisberg
Michael Gill
Hsien-Jue Chu
Yu-Wei Chiang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR056712A1 publication Critical patent/AR056712A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composiciones, incluyendo vacunas, y métodos para tratar, prevenir o mejorar la enfermedad del virus de la influenza canina (CIV) por medio de utilizar uno o más inmunogenes con cepa de virus de la influenza canina (CIV) o del virus de la influenza equina (EIV). También modelos de inoculacion utiles para determinar la eficacia de una composicion contra el virus de la influenza canina, que comprende una copa del virus de la influenza equina (EIV) o del virus de la influenza canina (CIV) de o inmunogenes de ellos.
ARP060104591A 2005-10-20 2006-10-20 Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus AR056712A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72866205P 2005-10-20 2005-10-20
US73529005P 2005-11-10 2005-11-10

Publications (1)

Publication Number Publication Date
AR056712A1 true AR056712A1 (es) 2007-10-17

Family

ID=37963233

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104591A AR056712A1 (es) 2005-10-20 2006-10-20 Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus

Country Status (5)

Country Link
US (1) US20070092537A1 (es)
EP (1) EP1941033A2 (es)
AR (1) AR056712A1 (es)
TW (1) TW200733972A (es)
WO (1) WO2007047728A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
WO2006116082A1 (en) * 2005-04-21 2006-11-02 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US20080107687A1 (en) * 2006-11-06 2008-05-08 Herve Poulet Feline vaccines against avian influenza
AU2011224507A1 (en) 2010-03-10 2012-08-30 Intervet International B.V. Method for protecting against disease caused by secondary pathogens
LT2670432T (lt) * 2011-02-04 2021-05-25 Zoetis Services Llc Imunogeninės bordetalla bronchiseptica kompozicijos
WO2012104820A1 (en) * 2011-02-04 2012-08-09 Pfizer Inc. Compositions for canine respiratory disease complex
CA2967532A1 (en) 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090393A (en) * 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
MXPA04000680A (es) * 2001-07-27 2004-04-05 Wyeth Corp Vacuna para virus west nile.
WO2006116082A1 (en) * 2005-04-21 2006-11-02 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7384642B2 (en) * 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
KR20110126726A (ko) * 2005-10-07 2011-11-23 화이자 프로덕츠 인코포레이티드 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use

Also Published As

Publication number Publication date
TW200733972A (en) 2007-09-16
WO2007047728A2 (en) 2007-04-26
WO2007047728A3 (en) 2007-08-02
US20070092537A1 (en) 2007-04-26
EP1941033A2 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
AR056712A1 (es) Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus
AR056566A1 (es) Vacunas y procedimientos para tratar la gripe canina
CO6160334A2 (es) Metodo para la elaboracion de una vacuna de conbinacion para proteger contra polio
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
EA200970013A1 (ru) Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
IN2012DN02736A (es)
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
AR065319A1 (es) Prevencion y tratamiento de pcvd subclinica
EA201201321A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
CY1110669T1 (el) Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης
MX2009006178A (es) Vacuna contra salmonela.
ATE554789T1 (de) Neues hundeinfluenza-virus und imfpstoff hierfür
AR056733A1 (es) Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
MX338898B (es) Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
AR047581A1 (es) Vacunas de calicivirus felino
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
TR201820975A2 (tr) İbuprofen, Psödoefedrin ve Erdostein İçeren Uzatılmış Salım Sağlayan Farmasötik Kompozisyon
CR9759A (es) Vacuna rotavirus que induce la proteccion cruzada heterotipica
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
ATE495758T1 (de) Virulentes systemisches felines calicivirus
BR112012022680A2 (pt) métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina

Legal Events

Date Code Title Description
FB Suspension of granting procedure